Valencia, Spain and New York, January 28, 2025 – Quibim, a healthtech firm centered on using imaging biomarkers for precision medication, introduced at the moment the shut of its $50 million Collection A financing.
The corporate mentioned it has skilled progress within the variety of sufferers analyzed by its merchandise over the previous 12 months. Pushed by a number of regulatory approvals and world business partnerships, affected person evaluation surged by 168% quarter-on-quarter. The financing was led by Asabys (via its fund Sabadell Asabys II) and Buenavista Fairness Companions (via the BHG I fund, created in partnership with Columbus Enterprise Companions), and joined by UI Investissements, and GoHub Ventures as new buyers. It was additionally joined by present buyers, Amadeus Capital Companions, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early progress fund), Tony Fadell’s Construct Collective, and particular person investor Dr. Jonathan Milner, founding father of Abcam plc.
Quibim is devoted to the bold mission of unlocking an entire, non-invasive understanding of each tissue level within the human physique, at any second in time. To realize this, the corporate develops foundational AI fashions utilized to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow exact characterization of phenotypes and prediction of outcomes in areas corresponding to oncology, immunology, neurology and metabolic issues.
That is the pathway towards attaining human digital twins, dynamic fashions that not solely replicate and permit well being monitoring but in addition improve affected person stratification, enhance the success charges of drug improvement applications, and allow therapy testing earlier than software. As we speak, the corporate is constructing digital twins on the organ and lesion degree, exemplified by options like QP-Mind, QP-Prostate, and QP-Liver.
Nevertheless, as the amount of whole-body scans and associated imaging information continues to develop, within the coming years Quibim fashions will analyze the complete physique. The imaginative and prescient of the corporate is to catalyze this revolutionary step in healthcare by merging imaging applied sciences, computing, and AI.
With over 170 installations worldwide, together with prestigious establishments like Mass Common Brigham and Stanford, and regulatory clearances throughout the US, EU, UK, and different areas, Quibim’s expertise bridges the hole between analysis, medical apply, and drug improvement. Final 12 months, Philips introduced a world partnership with Quibim to combine its AI fashions into MR scanners, whereas the corporate additionally secured strategic alliances with main biopharma giants corresponding to Merck KGaA and Novartis.
“Quibim’s mission is to show imaging right into a catalyst for precision well being, and we’re deeply grateful to each our new and present buyers for his or her help,” mentioned Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our world enlargement into the U.S. is a essential milestone as we work with pharmaceutical leaders and healthcare suppliers to unlock the facility of imaging to revolutionize diagnostics and enhance affected person outcomes.”
Quibim’s product portfolio consists of:
- QP-Prostate: the corporate’s flagship product is designed to reinforce prostate most cancers detection via an industry-leading AI-powered lesion detection*. CE, UKCA marked and 510(ok) cleared.
- QP-Mind: AI-based early-stage neurological illness quantification software program for quantification of early mind atrophy and lesions. CE, UKCA marked and 510(ok) cleared.
- QP-Liver: automated AI software for MR prognosis of diffuse liver ailments via correct quantification of tissue fats and iron ranges. CE and UKCA marked.
- QP-Insights: A platform to handle, retailer and analyze multi-omics information in medical trials and real-world information research. QP-Insights is being utilized by world biopharmaceutical firms, educational medical facilities and analysis consortiums, together with the European Most cancers Imaging Initiative to help Europe’s Beating Most cancers Plan. QP-Insights is the platform managing the biggest imaging datasets on the planet, accounting for greater than 100 million medical photos.
With the sequence A financing, Quibim is establishing a robust U.S. presence, constructing on its success in Europe, via strategic collaborations with hospitals and pharmaceutical firms. By implementing its strategic plan and, via its suite of options already cleared by FDA, the corporate will help healthcare suppliers and medical researchers to course of an unprecedented quantity of knowledge from medical scans. Moreover, Quibim’s AI-powered imaging options will empower pharmaceutical firms by enhancing medical trials and accelerating drug improvement with exact, actionable insights derived from imaging biomarkers.
“Asabys is thrilled to help Quibim in reworking the imaging diagnostics house,” mentioned Guillem Masferrer, Associate at Asabys Companions. “Their capability to mix AI with imaging biomarker discovery addresses essential unmet wants in oncology, neurology, and past. We’re assured that Quibim’s modern options could have a profound influence on world healthcare.”
“Quibim’s expertise exemplifies the following wave of precision medication,” mentioned José Mesa, Associate at Columbus and Buenavista’s consultant on the Board. “Their spectacular observe file with world pharmaceutical partnerships, together with partnerships with firms corresponding to Merck KGaA and Philips, exemplify Quibim’s position in reworking imaging information into useful predictions for medical trials and therapy planning. We count on that as Quibim develops its pipeline of companion diagnostic instruments, we are going to see super momentum for its expertise and merchandise.”
“The foundational analysis completed by Quibim’s workforce has not solely knowledgeable {industry} requirements, but in addition led to the corporate pioneering an method to combining radiomics and deep studying that’s now an ordinary of its personal.” mentioned Pierre Socha, Associate at Amadeus Capital Companions. “This platform method was novel on the time of our first funding and proved to be the correct technique for fast scale-up.”
“Excited that Quibim’s AI enabled insights from MRI, CT and PET scans are coming to the US! Their FDA accredited precision evaluation is already being utilized by docs to detect early indicators of ailments like most cancers and assist measure therapy response. Quibim has actually superior precision medication all over the world!” mentioned Tony Fadell Construct Collective Principal and Nest Founder.
